Koch Institute Summer Symposium 2021: Engineering the Next Wave of Immunotherapy

Cancer immunotherapy has revolutionized the landscape of cancer treatment, our thinking of tumor biology and clinical practice. Following the groundbreaking successes of checkpoint blockade therapy and CAR T cell therapy, culminating in multiple FDA-approved treatments and the awarding of the 2018 Nobel Prize in Medicine to Jim Allison and Tasuku Honjo, the field is currently at a critical juncture.

While checkpoint blockade therapy has demonstrated that the immune system can be harnessed to fight cancer, the next generation of treatments will require us to understand what causes resistance in non-responders, how this can be overcome, and how these issues are best addressed clinically. Discussing these questions will be at the core of this symposium as we move towards our ultimate goal to increase the number of patients benefiting from immunotherapy.


Targeting T Cells 
Rafi Ahmed, Michael Dougan, Chris Love

Thinking Beyond T Cells
Yasmine Belkaid, Juan Mendoza, Stefani Spranger, Lauren Zasadil

Engineering Clinical Translation  
Chris Garcia, Juliana Idoyaga, Crystal Mackall

Panel Discussion: Clinical Translation: A Real Life Perspective

Daniel Chen, Michael Dougan, Kimberly Shafer-Weaver
Moderators: Steven Silverstein, Jane Wilkinson

Thank You to Our Sponsors

Agilent Technologies, Inc.
Dragonfly Therapeutics, Inc.
Repertoire Immune Medicines
Ribon Therapeutics
Skyhawk Therapeutics

Download Event Flier Go to Event Web Page